Rep. Brad Knott Sells Off Shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)

Representative Brad Knott (R-North Carolina) recently sold shares of Oramed Pharmaceuticals Inc. NASDAQ: ORMP. In a filing disclosed on February 25th, the Representative disclosed that they had sold between $15,001 and $50,000 in Oramed Pharmaceuticals stock on January 10th. The trade occurred in the Representative's "CHARLES SCHWAB BROKERAGE ACCOUNT 1" account.

Representative Brad Knott also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of CompoSecure NASDAQ: CMPO on 1/14/2025.
• Purchased $1,001 - $15,000 in shares of CompoSecure NASDAQ: CMPO on 1/10/2025.

Oramed Pharmaceuticals Stock Performance

Shares of NASDAQ ORMP traded down $0.01 during trading on Friday, reaching $2.09. The stock had a trading volume of 58,677 shares, compared to its average volume of 323,366. The company has a market cap of $84.25 million, a P/E ratio of 19.00 and a beta of 1.66. The business's 50-day moving average price is $2.31 and its 200-day moving average price is $2.36. Oramed Pharmaceuticals Inc. has a fifty-two week low of $2.00 and a fifty-two week high of $3.48.

Analysts Set New Price Targets

Separately, StockNews.com lowered shares of Oramed Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Wednesday, February 19th.

Remove Ads

Institutional Investors Weigh In On Oramed Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Murchinson Ltd. grew its position in shares of Oramed Pharmaceuticals by 0.5% in the third quarter. Murchinson Ltd. now owns 1,708,879 shares of the biotechnology company's stock valued at $4,170,000 after purchasing an additional 8,889 shares during the last quarter. XTX Topco Ltd increased its holdings in shares of Oramed Pharmaceuticals by 59.7% during the 3rd quarter. XTX Topco Ltd now owns 24,716 shares of the biotechnology company's stock worth $60,000 after buying an additional 9,242 shares during the last quarter. Boothbay Fund Management LLC raised its holdings in shares of Oramed Pharmaceuticals by 2.0% in the 4th quarter. Boothbay Fund Management LLC now owns 845,188 shares of the biotechnology company's stock worth $2,045,000 after purchasing an additional 16,857 shares during the period. World Equity Group Inc. acquired a new position in Oramed Pharmaceuticals during the fourth quarter valued at approximately $48,000. Finally, Marquette Asset Management LLC acquired a new position in shares of Oramed Pharmaceuticals during the 4th quarter valued at $81,000. 12.73% of the stock is currently owned by hedge funds and other institutional investors.

About Representative Knott

Brad Knott (Republican Party) is a member of the U.S. House, representing North Carolina's 13th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Knott (Republican Party) ran for election to the U.S. House to represent North Carolina's 13th Congressional District. He won in the general election on November 5, 2024. Brad Knott grew up in Raleigh, North Carolina. He earned a J.D. from Wake Forest University. Knott's career experience includes working as a federal prosecutor in the U.S. Attorney’s Office for Eastern North Carolina.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.